 <h1>Tafasitamab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tafasitamab: intravenous powder for injection</i></p><h3>Warning</h3><p>Tafasitamab affects your immune system.  You may get infections more easily, even serious or fatal infections.  Call your doctor if you have signs of infection (fever, cough with mucus, chest tightness, shortness of breath, or pain or burning when you urinate).</p><p>This medicine may harm an unborn baby. Use effective birth control to prevent pregnancy while using tafasitamab and for at least 3 months after your last dose.</p><p>Carefully follow all instructions about the use of birth control while you are using tafasitamab in combination with lenalidomide.</p><p>Get emergency medical help if you have signs of an allergic reaction:  hives; difficult breathing; swelling of your face, lips, tongue, or throat.</p><p>Some side effects may occur during the injection.  Tell your caregiver if you feel chilled, warm, sweaty, anxious, or have a headache, trouble breathing, or pounding in your neck or ears.</p><p>Call your doctor at once if you have:</p><ul>
<li>
<p>cough with mucus, chest tightness, shortness of breath;</p>
</li>
<li>
<p>fever above 100.4 degrees F (38 degrees C);</p>
</li>
<li>
<p>pain or burning when you urinate;</p>
</li>
<li>
<p>easy bruising, unusual bleeding, purple or red spots under your skin;</p>
</li>
<li>
<p>low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or</p>
</li>
<li>
<p>low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing.</p>
</li>
</ul><p>cough with mucus, chest tightness, shortness of breath;</p><p>fever above 100.4 degrees F (38 degrees C);</p><p>pain or burning when you urinate;</p><p>easy bruising, unusual bleeding, purple or red spots under your skin;</p><p>low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or</p><p>low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough, trouble breathing.</p><p>Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.</p><p>Common side effects may include:</p><ul>
<li>
<p>low blood cell counts;</p>
</li>
<li>
<p>fever;</p>
</li>
<li>
<p>feeling weak or tired;</p>
</li>
<li>
<p>cough;</p>
</li>
<li>
<p>cold symptoms such as stuffy nose, sneezing, sore throat;</p>
</li>
<li>
<p>loss of appetite, diarrhea; or</p>
</li>
<li>
<p>swelling in your hands or lower legs.</p>
</li>
</ul><p>low blood cell counts;</p><p>fever;</p><p>feeling weak or tired;</p><p>cough;</p><p>cold symptoms such as stuffy nose, sneezing, sore throat;</p><p>loss of appetite, diarrhea; or</p><p>swelling in your hands or lower legs.</p><p>This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tafasitamab: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (51%), activated partial thromboplastin time increased (46%), anemia (36%), thrombocytopenia (31%), febrile neutropenia (12%)</p><p><b>Common</b> (1% to 10%): Lymphopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (73%), Grade 3 or higher infection (30%) </p><p><b>Common</b> (1% to 10%): Sepsis</p><p><b>Frequency not reported</b>: Potential immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion related reactions (IRRs) (e.g., chills, flushing, dyspnea, hypertension)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (19%), muscle spasms (15%)</p><p><b>Common</b> (1% to 10%): Arthralgia, pain in extremity, musculoskeletal pain</p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Glucose increased (49%), calcium decreased (47%), gamma glutamyl transferase increased (34%), albumin decreased (26%), magnesium decreased (22%), anorexia (22%), urate increased (20%), phosphate decreased (20%), hypokalemia (19%)</p><p><b>Common</b> (1% to 10%): Weight loss<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (e.g., urinary tract infection, Escherichia urinary tract infection, urinary tract infection bacterial, urinary tract infection enterococcal) (17%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Aspartate aminotransferase increased (20%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Basal cell carcinoma<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (26%), respiratory tract infection (e.g., lower respiratory tract infection, upper respiratory tract infection, respiratory tract infection) (24%), bronchitis (16%), dyspnea (12%), nasopharyngitis (10%), pneumonia (10%)</p><p><b>Common</b> (1% to 10%): Nasal congestion, exacerbation of obstructive pulmonary disease<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (38%), pyrexia (24%), peripheral edema (24%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions (20% or greater) were neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, and decreased appetite.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, paresthesia, dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (20%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Erythema, alopecia, hyperhidrosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (36%), constipation (17%), nausea (15%), vomiting (15%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Monjuvi (tafasitamab)." Morphosys US, Boston, MA. </p><h2>More about tafasitamab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tafasitamab-cxix Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diffuse Large B-Cell Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>